Omar L Esponda1, Robert Hunter2, José R Rivera Del Río2, A Valance Washington3. 1. Department of Internal Medicine, Hospital Universitario Dr Ramón Ruiz Arnau, Universidad Central del Caribe, Bayamón, PR, USA. 2. Department of Internal Medicine, Hospital Universitario Dr Ramón Ruiz Arnau, Universidad Central del Caribe, Bayamón, PR, USA Laboratory of Anatomy and Cell Biology, Hospital HIMA San Pablo, Bayamón, PR, USA. 3. Department of Biology, University of Puerto Rico-Rio Piedras, San Juan, PR, USA valancew@gmail.com.
Abstract
OBJECTIVE: Recent studies suggest that the soluble triggering receptor expressed on myeloid cells-like transcript 1 (sTLT-1) facilitate atherothrombosis. Therefore, we evaluated sTLT-1 as a functional measure of atherothrombosis in acute coronary syndrome (ACS). METHODS: Levels of sTLT-1 were determined by enzyme-linked immunosorbent assay on plasma from patients with potential ACS and compared with an age-matched control group with similar risk factors for cardiovascular disease. RESULTS: Of 53 patients enrolled, 19 patients were undergoing ACS (15 unstable angina, 2 non-ST-segment elevated myocardial infarction, and 2 ST-segment elevated myocardial infarction), 5 patients were found with noncardiac chest pain, and 29 were in the control group. The mean plasma sTLT-1 values in the ACS group were 4.644 ng/mL ± 1.277 standard error of the mean (SEM), in the noncardiac chest pain group were 0.708 ng/mL ± 0.427 SEM, and in the control group were 1.007 ng/mL ± 0.098 SEM. CONCLUSION: A statistically significant difference exists between patients experiencing cardiogenic chest pain versus controls (P < .05), suggesting sTLT-1 as a potential tool for understanding atherothrombosis in ACS.
OBJECTIVE: Recent studies suggest that the soluble triggering receptor expressed on myeloid cells-like transcript 1 (sTLT-1) facilitate atherothrombosis. Therefore, we evaluated sTLT-1 as a functional measure of atherothrombosis in acute coronary syndrome (ACS). METHODS: Levels of sTLT-1 were determined by enzyme-linked immunosorbent assay on plasma from patients with potential ACS and compared with an age-matched control group with similar risk factors for cardiovascular disease. RESULTS: Of 53 patients enrolled, 19 patients were undergoing ACS (15 unstable angina, 2 non-ST-segment elevated myocardial infarction, and 2 ST-segment elevated myocardial infarction), 5 patients were found with noncardiac chest pain, and 29 were in the control group. The mean plasma sTLT-1 values in the ACS group were 4.644 ng/mL ± 1.277 standard error of the mean (SEM), in the noncardiac chest pain group were 0.708 ng/mL ± 0.427 SEM, and in the control group were 1.007 ng/mL ± 0.098 SEM. CONCLUSION: A statistically significant difference exists between patients experiencing cardiogenic chest pain versus controls (P < .05), suggesting sTLT-1 as a potential tool for understanding atherothrombosis in ACS.
Authors: Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley Journal: Nat Med Date: 2002-12-16 Impact factor: 53.440
Authors: Andreas Schober; David Manka; Philipp von Hundelshausen; Yuqing Huo; Peter Hanrath; Ian J Sarembock; Klaus Ley; Christian Weber Journal: Circulation Date: 2002-09-17 Impact factor: 29.690
Authors: A Valance Washington; Rebecca L Schubert; Laura Quigley; Theresa Disipio; Robert Feltz; Edward H Cho; Daniel W McVicar Journal: Blood Date: 2004-04-20 Impact factor: 22.113
Authors: Marieli Gonzalez-Cotto; Liang Guo; Megan Karwan; Shurjo K Sen; Jennifer Barb; Carlos J Collado; Fathi Elloumi; Erika M Palmieri; Kimberly Boelte; Frank D Kolodgie; Aloke V Finn; Leslie G Biesecker; Daniel W McVicar Journal: Front Immunol Date: 2020-03-30 Impact factor: 7.561